REMARKS

The claims have been amended to remove the multiple dependency therein.

The Commissioner is hereby authorized to charge any fees associated with this response or credit any overpayment to Deposit Account No. 13-3402.

Respectfully submitted,

Richard J. Traverso, Reg. No. 30,595

Attorney for Applicant(s)

MILLEN, WHITE, ZELANO & BRANIGAN, P.C. Arlington Courthouse Plaza 1, Suite 1400 2200 Clarendon Boulevard Arlington, Virginia 22201 Telephone: (703) 243-6333

Attorney Docket No.: SCH-1805

Date: September 3, 2002

Facsimile: (703) 243-6410

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE CLAIMS:

Please amend the claims as follows:

- 3. (Amended) Compounds according to claim 1 or 2, wherein R1 is the group -CO-R11.
- 5. (Amended) Compounds according to claim 1 or 2, wherein R1 is the group -CO-OR12.
- 7. (Amended) Compounds according to one of claims 1 to 6 claim 1, wherein R2 is a 2',5'-difluorobenzyl group.
- 8. (Amended) Compounds according to one of claims 1 to 7 claim 1, wherein R3 and R4 are hydrogen atoms.
- 9. (Amended) Compounds according to one of claims 1 to 8 claim 1, wherein Z is a direct bond or an oxygen atom.
 - 10. (Amended) Compounds according to one of claims 1 to 9 claim 1, wherein G C = C
- 11. (Amended) Compounds according to one of claims 1 to 10 claim 1, wherein L is an NH group.
- 12. (Amended) Compounds according to one of claims 1 to 11 claim 1, wherein Q is a carbonyl group, and R51 is a C₁-C₆ alkyl group.
- 13. (Amended) Compounds according to one of claims 1 to 12 claim 1, wherein R61 is a hydrogen atom or a methyl group and/or R62 is a benzyl group.
- 14. (Amended) Use of compounds according to one of claims 1 to 13 claim 1 as antagonists of the gonadotropin-releasing hormone (GnRH).